About ImageneBio Inc
https://www.inmagenebio.comClinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis.
CEO
Kristin Yarema
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-07-28 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
OMEGA FUND MANAGEMENT, LLC
Shares:455.36K
Value:$3.11M
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC
Shares:377.81K
Value:$2.58M
JACOBS LEVY EQUITY MANAGEMENT, INC
Shares:17.71K
Value:$120.95K
Summary
Showing Top 3 of 4
About ImageneBio Inc
https://www.inmagenebio.comClinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $26.59M ▲ | $-24.78M ▼ | 0% | $-3.01 ▼ | $-24.76M ▼ |
| Q2-2025 | $0 | $8.71M ▲ | $-2.77M ▲ | 0% | $-0.06 ▲ | $-8.35M ▲ |
| Q1-2025 | $0 | $7.08M ▼ | $-8.62M ▲ | 0% | $-0.18 ▲ | $-9.27M ▲ |
| Q4-2024 | $0 | $7.94M ▲ | $-9.12M ▲ | 0% | $-0.19 ▲ | $-12.09M ▼ |
| Q3-2024 | $0 | $5.59M | $-10.23M | 0% | $-0.21 | $-11.51M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $142.58M ▲ | $160.88M ▲ | $21.05M ▲ | $139.83M ▲ |
| Q2-2025 | $95.64M ▼ | $126.17M ▼ | $10.26M ▼ | $115.91M ▼ |
| Q1-2025 | $114.05M ▼ | $130.84M ▼ | $12.59M ▼ | $118.25M ▼ |
| Q4-2024 | $124.39M ▼ | $141.51M ▼ | $15.58M ▲ | $125.93M ▼ |
| Q3-2024 | $138.03M | $148.99M | $14.76M | $134.23M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-24.78M ▼ | $-26.64M ▼ | $-37.33M ▼ | $135.47M ▲ | $44.87M ▲ | $-26.64M ▼ |
| Q2-2025 | $-2.77M ▲ | $-3.42M ▲ | $24.95M ▲ | $0 | $21.53M ▲ | $-3.42M ▲ |
| Q1-2025 | $-8.62M ▲ | $-10.56M ▼ | $7.93M ▲ | $0 | $-2.63M ▲ | $-10.56M ▼ |
| Q4-2024 | $-9.12M ▲ | $-6.26M ▲ | $463K ▼ | $0 | $-5.8M ▼ | $-6.26M ▲ |
| Q3-2024 | $-10.23M | $-8.94M | $9.45M | $0 | $516K | $-8.94M |
CEO
Kristin Yarema
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-07-28 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
OMEGA FUND MANAGEMENT, LLC
Shares:455.36K
Value:$3.11M
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC
Shares:377.81K
Value:$2.58M
JACOBS LEVY EQUITY MANAGEMENT, INC
Shares:17.71K
Value:$120.95K
Summary
Showing Top 3 of 4